{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T05:05:16Z","timestamp":1794287116208,"version":"4.9.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,3,22]],"date-time":"2021-03-22T00:00:00Z","timestamp":1616371200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,3,22]],"date-time":"2021-03-22T00:00:00Z","timestamp":1616371200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cancer"],"DOI":"10.1038\/s43018-021-00185-w","type":"journal-article","created":{"date-parts":[[2021,3,22]],"date-time":"2021-03-22T17:02:57Z","timestamp":1616432577000},"page":"444-456","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":244,"title":["EZH2 inhibition activates a dsRNA\u2013STING\u2013interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer"],"prefix":"10.1038","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7968-4032","authenticated-orcid":false,"given":"Katherine L.","family":"Morel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali V.","family":"Sheahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah L.","family":"Burkhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvan C.","family":"Baca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Boufaied","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8560-7017","authenticated-orcid":false,"given":"Xintao","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Israel","family":"Ca\u00f1adas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Roehle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Heckler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Calagua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huihui","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2750-9352","authenticated-orcid":false,"given":"Constantia","family":"Pantelidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5391-598X","authenticated-orcid":false,"given":"Phillip","family":"Galbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukanya","family":"Panja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0671-6512","authenticated-orcid":false,"given":"Antonina","family":"Mitrofanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2613-8425","authenticated-orcid":false,"given":"Scott","family":"Wilkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nichelle C.","family":"Whitlock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shana Y.","family":"Trostel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anis A.","family":"Hamid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam S.","family":"Kibel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5422-4275","authenticated-orcid":false,"given":"David A.","family":"Barbie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atish D.","family":"Choudhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark M.","family":"Pomerantz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Sweeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6849-6629","authenticated-orcid":false,"given":"Henry W.","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Einstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey I.","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie K.","family":"Dougan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2760-1853","authenticated-orcid":false,"given":"Adam G.","family":"Sowalsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Housheng Hansen","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0151-1238","authenticated-orcid":false,"given":"Matthew L.","family":"Freedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4546-7371","authenticated-orcid":false,"given":"Steven P.","family":"Balk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Loda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8864-8765","authenticated-orcid":false,"given":"David P.","family":"Labb\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian M.","family":"Olson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4739-5049","authenticated-orcid":false,"given":"Leigh","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,22]]},"reference":[{"key":"185_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2019. CA Cancer J. Clin. 69, 7\u201334 (2019).","journal-title":"CA Cancer J. Clin."},{"key":"185_CR2","volume":"6","author":"L Gan","year":"2018","unstructured":"Gan, L. et al. Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential. Biomark Res. 6, 10 (2018).","journal-title":"Biomark Res."},{"key":"185_CR3","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/nature01075","volume":"419","author":"S Varambally","year":"2002","unstructured":"Varambally, S. et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419, 624\u2013629 (2002).","journal-title":"Nature"},{"key":"185_CR4","doi-asserted-by":"crossref","first-page":"669","DOI":"10.18632\/oncotarget.327","volume":"2","author":"CM Koh","year":"2011","unstructured":"Koh, C. M. et al. Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post-transcriptional mechanisms. Oncotarget 2, 669\u2013683 (2011).","journal-title":"Oncotarget"},{"key":"185_CR5","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nature15520","volume":"527","author":"D Peng","year":"2015","unstructured":"Peng, D. et al. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature 527, 249\u2013253 (2015).","journal-title":"Nature"},{"key":"185_CR6","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1158\/2159-8290.CD-18-1090","volume":"9","author":"D Ennishi","year":"2019","unstructured":"Ennishi, D. et al. Molecular and genetic characterization of MHC deficiency identifies EZH2 as therapeutic target for enhancing immune recognition. Cancer Discov. 9, 546\u2013563 (2019).","journal-title":"Cancer Discov."},{"key":"185_CR7","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ccell.2019.08.008","volume":"36","author":"ML Burr","year":"2019","unstructured":"Burr, M. L. et al. An evolutionarily conserved function of polycomb silences the MHC class I antigen presentation pathway and enables immune evasion in cancer. Cancer Cell 36, 385\u2013401 e388 (2019).","journal-title":"Cancer Cell"},{"key":"185_CR8","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.cell.2015.07.056","volume":"162","author":"D Roulois","year":"2015","unstructured":"Roulois, D. et al. DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts. Cell 162, 961\u2013973 (2015).","journal-title":"Cell"},{"key":"185_CR9","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1158\/0008-5472.CAN-15-1938","volume":"76","author":"N Nagarsheth","year":"2016","unstructured":"Nagarsheth, N. et al. PRC2 epigenetically silences Th1-type chemokines to suppress effector T-cell trafficking in colon cancer. Cancer Res. 76, 275\u2013282 (2016).","journal-title":"Cancer Res."},{"key":"185_CR10","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.cell.2018.05.052","volume":"174","author":"W Sheng","year":"2018","unstructured":"Sheng, W. et al. LSD1 ablation stimulates anti-tumor immunity and enables checkpoint blockade. Cell 174, 549\u2013563 e519 (2018).","journal-title":"Cell"},{"key":"185_CR11","doi-asserted-by":"crossref","first-page":"E10981","DOI":"10.1073\/pnas.1712514114","volume":"114","author":"ML Stone","year":"2017","unstructured":"Stone, M. L. et al. Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden. Proc. Natl Acad. Sci. USA 114, E10981\u2013E10990 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"185_CR12","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.celrep.2017.07.007","volume":"20","author":"D Zingg","year":"2017","unstructured":"Zingg, D. et al. The histone methyltransferase Ezh2 controls mechanisms of adaptive resistance to tumor immunotherapy. Cell Rep. 20, 854\u2013867 (2017).","journal-title":"Cell Rep."},{"key":"185_CR13","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1158\/2159-8290.CD-16-1020","volume":"7","author":"DO Adeegbe","year":"2017","unstructured":"Adeegbe, D. O. et al. Synergistic immunostimulatory effects and therapeutic benefit of combined histone deacetylase and bromodomain inhibition in non-small cell lung cancer. Cancer Discov. 7, 852\u2013867 (2017).","journal-title":"Cancer Discov."},{"key":"185_CR14","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/j.celrep.2017.02.011","volume":"18","author":"SJ Hogg","year":"2017","unstructured":"Hogg, S. J. et al. BET-bromodomain inhibitors engage the host immune system and regulate expression of the immune checkpoint ligand PD-L1. Cell Rep. 18, 2162\u20132174 (2017).","journal-title":"Cell Rep."},{"key":"185_CR15","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.celrep.2014.05.045","volume":"8","author":"ZN Wee","year":"2014","unstructured":"Wee, Z. N. et al. EZH2-mediated inactivation of IFN-gamma-JAK-STAT1 signaling is an effective therapeutic target in MYC-driven prostate cancer. Cell Rep. 8, 204\u2013216 (2014).","journal-title":"Cell Rep."},{"key":"185_CR16","doi-asserted-by":"crossref","first-page":"e20659","DOI":"10.1200\/JCO.2016.34.15_suppl.e20659","volume":"34","author":"ML Johnson","year":"2016","unstructured":"Johnson, M. L. et al. Preliminary results of ENCORE 601, a phase 1b\/2, open-label study of entinostat (ENT) in combination with pembrolizumab (PEMBRO) in patients with non-small cell lung cancer (NSCLC). J. Clin. Oncol. 34, e20659\u2013e20659 (2016).","journal-title":"J. Clin. Oncol."},{"key":"185_CR17","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/pros.23206","volume":"76","author":"L Ellis","year":"2016","unstructured":"Ellis, L. et al. Generation of a C57BL\/6 MYC-driven mouse model and cell line of prostate cancer. Prostate 76, 1192\u20131202 (2016).","journal-title":"Prostate"},{"key":"185_CR18","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.stem.2013.10.001","volume":"14","author":"H Xie","year":"2014","unstructured":"Xie, H. et al. Polycomb repressive complex 2 regulates normal hematopoietic stem cell function in a developmental-stage-specific manner. Cell Stem Cell 14, 68\u201380 (2014).","journal-title":"Cell Stem Cell"},{"key":"185_CR19","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1073\/pnas.0712021105","volume":"105","author":"CK Ratnacaram","year":"2008","unstructured":"Ratnacaram, C. K. et al. Temporally controlled ablation of PTEN in adult mouse prostate epithelium generates a model of invasive prostatic adenocarcinoma. Proc. Natl Acad. Sci. USA 105, 2521\u20132526 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"185_CR20","first-page":"328rv324","volume":"8","author":"W Zou","year":"2016","unstructured":"Zou, W., Wolchok, J. D. & Chen, L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci. Transl. Med. 8, 328rv324 (2016).","journal-title":"Sci. Transl. Med."},{"key":"185_CR21","doi-asserted-by":"crossref","first-page":"10657","DOI":"10.1158\/0008-5472.CAN-07-2498","volume":"67","author":"J Yu","year":"2007","unstructured":"Yu, J. et al. A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res. 67, 10657\u201310663 (2007).","journal-title":"Cancer Res."},{"key":"185_CR22","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41568-019-0109-9","volume":"19","author":"PA Jones","year":"2019","unstructured":"Jones, P. A., Ohtani, H., Chakravarthy, A. & De Carvalho, D. D. Epigenetic therapy in immune-oncology. Nat. Rev. Cancer 19, 151\u2013161 (2019).","journal-title":"Nat. Rev. Cancer"},{"key":"185_CR23","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1038\/s41591-018-0116-5","volume":"24","author":"I Canadas","year":"2018","unstructured":"Canadas, I. et al. Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses. Nat. Med. 24, 1143\u20131150 (2018).","journal-title":"Nat. Med."},{"key":"185_CR24","doi-asserted-by":"crossref","first-page":"587","DOI":"10.18632\/oncotarget.1782","volume":"5","author":"H Li","year":"2014","unstructured":"Li, H. et al. Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. Oncotarget 5, 587\u2013598 (2014).","journal-title":"Oncotarget"},{"key":"185_CR25","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.cell.2015.10.020","volume":"164","author":"KB Chiappinelli","year":"2016","unstructured":"Chiappinelli, K. B. et al. Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. Cell 164, 1073 (2016).","journal-title":"Cell"},{"key":"185_CR26","doi-asserted-by":"crossref","unstructured":"Kim, J. et al. Polycomb- and methylation-independent roles of EZH2 as a transcription activator. Cell Rep. 25, 2808\u20132820 e2804 (2018).","DOI":"10.1016\/j.celrep.2018.11.035"},{"key":"185_CR27","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1038\/ng.3419","volume":"47","author":"MM Pomerantz","year":"2015","unstructured":"Pomerantz, M. M. et al. The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis. Nat. Genet. 47, 1346\u20131351 (2015).","journal-title":"Nat. Genet."},{"key":"185_CR28","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/s41588-020-0664-8","volume":"52","author":"MM Pomerantz","year":"2020","unstructured":"Pomerantz, M. M. et al. Prostate cancer reactivates developmental epigenomic programs during metastatic progression. Nat. Genet. 52, 790\u2013799 (2020).","journal-title":"Nat. Genet."},{"key":"185_CR29","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/nature23306","volume":"548","author":"DR Robinson","year":"2017","unstructured":"Robinson, D. R. et al. Integrative clinical genomics of metastatic cancer. Nature 548, 297\u2013303 (2017).","journal-title":"Nature"},{"key":"185_CR30","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers, M. et al. IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Invest. 127, 2930\u20132940 (2017).","journal-title":"J. Clin. Invest."},{"key":"185_CR31","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.immuni.2013.10.003","volume":"39","author":"G Bindea","year":"2013","unstructured":"Bindea, G. et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 39, 782\u2013795 (2013).","journal-title":"Immunity"},{"key":"185_CR32","doi-asserted-by":"publisher","unstructured":"Su, W. et al. The polycomb repressor complex 1 drives double-negative prostate cancer metastasis by coordinating stemness and immune suppression. Cancer Cell https:\/\/doi.org\/10.1016\/j.ccell.2019.06.009 (2019).","DOI":"10.1016\/j.ccell.2019.06.009"},{"key":"185_CR33","doi-asserted-by":"crossref","unstructured":"Rexer, H., Graefen, M., Merseburger, A. & AUO. Phase II study of pembrolizumab (MK-3475) in patients with metastatic castration-resistant prostate cancer (KEYNOTE-199)-study AP 93\/16 of the AUO. (In German) Urologe A 56, 1471\u20131472 (2017).","DOI":"10.1007\/s00120-017-0519-9"},{"key":"185_CR34","doi-asserted-by":"crossref","first-page":"5185","DOI":"10.1172\/JCI125184","volume":"128","author":"DN Rodrigues","year":"2018","unstructured":"Rodrigues, D. N. et al. Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. J. Clin. Invest. 128, 5185 (2018).","journal-title":"J. Clin. Invest."},{"key":"185_CR35","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/j.cell.2018.04.034","volume":"173","author":"YM Wu","year":"2018","unstructured":"Wu, Y. M. et al. Inactivation of CDK12 delineates a distinct immunogenic class of advanced prostate cancer. Cell 173, 1770\u20131782.e1714 (2018).","journal-title":"Cell"},{"key":"185_CR36","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nature25015","volume":"553","author":"J Zhang","year":"2018","unstructured":"Zhang, J. et al. Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance. Nature 553, 91\u201395 (2018).","journal-title":"Nature"},{"key":"185_CR37","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41586-018-0266-0","volume":"559","author":"A Calcinotto","year":"2018","unstructured":"Calcinotto, A. et al. IL-23 secreted by myeloid cells drives castration-resistant prostate cancer. Nature 559, 363\u2013369 (2018).","journal-title":"Nature"},{"key":"185_CR38","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1016\/j.celrep.2018.05.050","volume":"23","author":"D Wang","year":"2018","unstructured":"Wang, D. et al. Targeting EZH2 reprograms intratumoral regulatory T cells to enhance cancer immunity. Cell Rep. 23, 3262\u20133274 (2018).","journal-title":"Cell Rep"},{"key":"185_CR39","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.immuni.2013.09.012","volume":"39","author":"DJ Tumes","year":"2013","unstructured":"Tumes, D. J. et al. The polycomb protein Ezh2 regulates differentiation and plasticity of CD4+ T helper type 1 and type 2 cells. Immunity 39, 819\u2013832 (2013).","journal-title":"Immunity"},{"key":"185_CR40","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.molcel.2018.01.015","volume":"69","author":"AA Soshnev","year":"2018","unstructured":"Soshnev, A. A., Josefowicz, S. Z. & Allis, C. D. Greater than the sum of parts: complexity of the dynamic epigenome. Mol. Cell 69, 533 (2018).","journal-title":"Mol. Cell"},{"key":"185_CR41","doi-asserted-by":"crossref","first-page":"3813","DOI":"10.1172\/JCI99760","volume":"128","author":"S Goswami","year":"2018","unstructured":"Goswami, S. et al. Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy. J. Clin. Invest. 128, 3813\u20133818 (2018).","journal-title":"J. Clin. Invest."},{"key":"185_CR42","doi-asserted-by":"crossref","first-page":"20908","DOI":"10.18632\/oncotarget.24556","volume":"9","author":"AE de Groot","year":"2018","unstructured":"de Groot, A. E. & Pienta, K. J. Epigenetic control of macrophage polarization: implications for targeting tumor-associated macrophages. Oncotarget 9, 20908\u201320927 (2018).","journal-title":"Oncotarget"},{"key":"185_CR43","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S1535-6108(03)00215-0","volume":"4","author":"S Wang","year":"2003","unstructured":"Wang, S. et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 4, 209\u2013221 (2003).","journal-title":"Cancer Cell"},{"key":"185_CR44","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0925-4773(00)00551-7","volume":"101","author":"X Wu","year":"2001","unstructured":"Wu, X. et al. Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mech. Dev. 101, 61\u201369 (2001).","journal-title":"Mech. Dev."},{"key":"185_CR45","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.molcel.2008.10.016","volume":"32","author":"X Shen","year":"2008","unstructured":"Shen, X. et al. EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency. Mol. Cell 32, 491\u2013502 (2008).","journal-title":"Mol. Cell"},{"key":"185_CR46","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1535-6108(03)00197-1","volume":"4","author":"K Ellwood-Yen","year":"2003","unstructured":"Ellwood-Yen, K. et al. Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 4, 223\u2013238 (2003).","journal-title":"Cancer Cell"},{"key":"185_CR47","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nprot.2016.006","volume":"11","author":"J Drost","year":"2016","unstructured":"Drost, J. et al. Organoid culture systems for prostate epithelial and cancer tissue. Nat. Protoc. 11, 347\u2013358 (2016).","journal-title":"Nat. Protoc."},{"key":"185_CR48","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1126\/science.aah4199","volume":"355","author":"SY Ku","year":"2017","unstructured":"Ku, S. Y. et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science 355, 78\u201383 (2017).","journal-title":"Science"},{"key":"185_CR49","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1038\/nprot.2013.143","volume":"8","author":"FA Ran","year":"2013","unstructured":"Ran, F. A. et al. Genome engineering using the CRISPR-Cas9 system. Nat. Protoc. 8, 2281\u20132308 (2013).","journal-title":"Nat. Protoc."},{"key":"185_CR50","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1158\/2159-8290.CD-18-1218","volume":"9","author":"C Pantelidou","year":"2019","unstructured":"Pantelidou, C. et al. PARP inhibitor efficacy depends on CD8+ T-cell recruitment via intratumoral STING pathway activation in BRCA-deficient models of triple-negative breast cancer. Cancer Discov. 9, 722\u2013737 (2019).","journal-title":"Cancer Discov."},{"key":"185_CR51","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. Nat. Methods 9, 676\u2013682 (2012).","journal-title":"Nat. Methods"},{"key":"185_CR52","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2144\/000112257","volume":"42","author":"MR Lamprecht","year":"2007","unstructured":"Lamprecht, M. R., Sabatini, D. M. & Carpenter, A. E. CellProfiler: free, versatile software for automated biological image analysis. Biotechniques 42, 71\u201375 (2007).","journal-title":"Biotechniques"},{"key":"185_CR53","doi-asserted-by":"crossref","first-page":"6812","DOI":"10.1158\/1078-0432.CCR-17-0807","volume":"23","author":"C Calagua","year":"2017","unstructured":"Calagua, C. et al. Expression of PD-L1 in hormone-naive and treated prostate cancer patients receiving neoadjuvant abiraterone acetate plus prednisone and leuprolide. Clin. Cancer Res. 23, 6812\u20136822 (2017).","journal-title":"Clin. Cancer Res."},{"key":"185_CR54","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1373\/clinchem.2008.112797","volume":"55","author":"SA Bustin","year":"2009","unstructured":"Bustin, S. A. et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin. Chem. 55, 611\u2013622 (2009).","journal-title":"Clin. Chem."},{"key":"185_CR55","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"185_CR56","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/nbt.1621","volume":"28","author":"C Trapnell","year":"2010","unstructured":"Trapnell, C. et al. Transcript assembly and quantification by RNA-seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat. Biotechnol. 28, 511\u2013515 (2010).","journal-title":"Nat. Biotechnol."},{"key":"185_CR57","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1038\/nmeth.2688","volume":"10","author":"JD Buenrostro","year":"2013","unstructured":"Buenrostro, J. D., Giresi, P. G., Zaba, L. C., Chang, H. Y. & Greenleaf, W. J. Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position. Nat. Methods 10, 1213\u20131218 (2013).","journal-title":"Nat. Methods"},{"key":"185_CR58","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/nmeth.4396","volume":"14","author":"MR Corces","year":"2017","unstructured":"Corces, M. R. et al. An improved ATAC-seq protocol reduces background and enables interrogation of frozen tissues. Nat. Methods 14, 959\u2013962 (2017).","journal-title":"Nat. Methods"},{"key":"185_CR59","volume":"10","author":"B Langmead","year":"2009","unstructured":"Langmead, B., Trapnell, C., Pop, M. & Salzberg, S. L. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 10, R25 (2009).","journal-title":"Genome Biol."},{"key":"185_CR60","volume":"9","author":"Y Zhang","year":"2008","unstructured":"Zhang, Y. et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol. 9, R137 (2008).","journal-title":"Genome Biol."},{"key":"185_CR61","doi-asserted-by":"publisher","unstructured":"Bourgey, M. et al. GenPipes: an open-source framework for distributed and scalable genomic analyses. Gigascience 8, https:\/\/doi.org\/10.1093\/gigascience\/giz037 (2019).","DOI":"10.1093\/gigascience\/giz037"},{"key":"185_CR62","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1186\/1471-2105-11-237","volume":"11","author":"LJ Zhu","year":"2010","unstructured":"Zhu, L. J. et al. ChIPpeakAnno: a Bioconductor package to annotate ChIP-seq and ChIP-chip data. BMC Bioinformatics 11, 237 (2010).","journal-title":"BMC Bioinformatics"},{"key":"185_CR63","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1093\/bioinformatics\/btv145","volume":"31","author":"G Yu","year":"2015","unstructured":"Yu, G., Wang, L. G. & He, Q. Y. ChIPseeker: an R\/Bioconductor package for ChIP peak annotation, comparison and visualization. Bioinformatics 31, 2382\u20132383 (2015).","journal-title":"Bioinformatics"},{"key":"185_CR64","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/msb.2010.31","volume":"6","author":"C Lefebvre","year":"2010","unstructured":"Lefebvre, C. et al. A human B-cell interactome identifies MYB and FOXM1 as master regulators of proliferation in germinal centers. Mol. Syst. Biol. 6, 377 (2010).","journal-title":"Mol. Syst. Biol."},{"key":"185_CR65","doi-asserted-by":"crossref","first-page":"D607","DOI":"10.1093\/nar\/gky1131","volume":"47","author":"D Szklarczyk","year":"2019","unstructured":"Szklarczyk, D. et al. STRING v11: protein\u2013protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 47, D607\u2013D613 (2019).","journal-title":"Nucleic Acids Res."},{"key":"185_CR66","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1158\/2159-8290.CD-11-0130","volume":"1","author":"H Beltran","year":"2011","unstructured":"Beltran, H. et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov. 1, 487\u2013495 (2011).","journal-title":"Cancer Discov."},{"key":"185_CR67","doi-asserted-by":"crossref","first-page":"11428","DOI":"10.1073\/pnas.1902651116","volume":"116","author":"W Abida","year":"2019","unstructured":"Abida, W. et al. Genomic correlates of clinical outcome in advanced prostate cancer. Proc. Natl Acad. Sci. USA 116, 11428\u201311436 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"}],"container-title":["Nature Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43018-021-00185-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-021-00185-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-021-00185-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T21:08:58Z","timestamp":1670101738000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43018-021-00185-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,22]]},"references-count":67,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,4]]}},"alternative-id":["185"],"URL":"https:\/\/doi.org\/10.1038\/s43018-021-00185-w","relation":{},"ISSN":["2662-1347"],"issn-type":[{"value":"2662-1347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,22]]},"assertion":[{"value":"11 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}